Ligand Pharmaceuticals Inc General Contingent Value Rt

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator

Ligand to Report First Quarter 2026 Financial Results on May 7, 2026

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS

Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team

Ligand Reports Fourth Quarter and Full Year 2025 Financial Results